

Candida auris is an emerging multidrug-resistant fungus that can cause invasive infections associated with high mortality due to its high resistance to antifungals. C. auris has been in the U.S. since 2016 and other states have been successfully providing care to patients with *C. auris*.

NE ICAP and the DHHS HAI/AR program are ready to support any facility with the resources and education needed to provide safe care to all patients.

Infection Control Guidance: Candida auris | Candida auris (C. auris) | CDC

Recommended pi	recautions for	dialysis	facilities	with	patients	with C	. auris
----------------	----------------	----------	------------	------	----------	--------	---------

Re	comm	nended precautions for dialysis facilities with patients with C. auris				
	Comm	nunication: Flag chart and notify receiving facilities.				
	Educate all staff, including environmental services.					
	0	Reinforce hand hygiene practices.				
	0	Appropriate precautions				
	0	Re-educate on doffing and donning procedures.				
	Hand Hygiene:					
	0	Monitor hand hygiene compliance-increase observations.				
	0	ABHR is the preferred method unless hands are visibly dirty or soiled.				
	Minimizing exposure/Contact Isolation (Transmission based precautions).					
	0	Designate an area where patients with <i>C. auris</i> receive their dialysis treatment.				
		Preferably at a station away from others, with as few adjacent stations as possible				
		(utilize dedicated isolation room if available and not in use by Hepatitis B				
		patients).				
	0	Healthcare providers should wear gloves and an isolation gown over their				
		clothing while caring for patients with <i>C. auris</i> .				

- Reuse or extended use of PPE is not recommended when taking care of patients
- with C. auris. Remove PPEs when leaving the designated C. auris treatment area, and don new PPE when returning to the patient.
- o Dedicate reusable equipment for the patient (stethoscope, blood pressure cuffs, thermometers, blood glucose meters).
- o Limit patient movement in facility upon entry.
  - Entry-weigh patient
  - Dialyze on the last shift of the day.
  - Maintain separation from other patients.
- ☐ Environmental Cleaning and Disinfection
  - Utilize an EPA-approved disinfect for C. auris and assure it is used according to instructions for use and for the recommended contact time.
    - List P: Antimicrobial Products Registered with EPA for Claims Against Candida Auris | US EPA
      - Sodium Hypochlorite 1000 ppm: 2-minute contact time.
  - Clean and disinfect reusable equipment (even dedicated equipment)

Clean and disinfect the station immediately after use.
Change mop head, clean clothes, or use disposable after disinfecting the station.
Clean and disinfect any areas the patient used: restroom, hand hygiene sinks,
If the facility accepts a new *C. auris* patient from outside of the State, notify the Department of Public Health HAI/AR Department at 402-219-3115.
Interfacility transfer should include information regarding transmission-based precautions for MDROs, including *C. auris*. Include any relevant microbiological results.
A dialysis infection control specialist at ICAP is available to meet your needs. Call our hotline at 402-552-2881.

## **Resources:**

Candida auris - APIC

Candida Auris: Recommendations for Healthcare Outbreak Response | CORHA

<u>JoF | Free Full-Text | Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings (mdpi.com)</u>

Candida auris Dry Surface Biofilm (DSB) for Disinfectant Efficacy Testing - PMC (nih.gov)

Version 2.0

**Reviewed** 8/23/24